EGFR and non-small cell lung carcinoma: This then begs the question as to whether the mutation-positive groups have different underlying pathogenetic mechanisms and require different biomarkers and treatments, analogous to how patients with epidermal growth factor receptor-mutation-positive non-small cell lung cancer respond to tyrosine kinase inhibition, although the majority of patients with non-small cell lung cancer do not.